Bimatoprost administration

The ocular hypotensive lipids in typical ophthalmology practice are considered first-line alternatives to topical P-blockers because of their superior efficacy and safety profiles. Many clinicians may choose to use the ocular hypotensive lipids as first-line agents, especially in patients that have an initial requirement to lower IOP by more than 25%, or in patients that have relative or absolute contraindications to topical P-blockers. However, latanoprost is currently the only ocular hypotensive lipid drug that has a Food and Drug Administration (FDA) indication for first-line therapy. Bimatoprost and travoprost are indicated by the FDA for patients who are intolerant of other IOP-lowering therapy or insufficiently responsive to another IOP-lowering medication.10,38... 

BIMATOPROST, LATANOPROST, TRAVOPROST The recommended dosage is 1 drop in the affected eye(s) once daily in the evening. Do not exceed once-daily dosage because it has been shown that more frequent administration may decrease the lOP-lowering effect. 

BImatoprost. Bimatoprost (Lumigan) is supplied as a sterile 0.03% ophthalmic solution in 2.5- and S.O-mL sizes. The recommended dosage of bimatoprost is limited to one drop into the affected eye once daily in the evening. Increased use may decrease its beneftcial effect. If used concurrently with other lOP-lowering drugs, a waiting period of S minutes should separate administrations. 

Sensory systems A case series of three patients who presented with periocular changes in the treated eye following chronic administration of unilateral latanoprost 0.005% has appeared published [53 ]. The clinical changes included worsening of dermatochalasis, deepening of superior sulcus and hollowness of the lid. This similar observation was previously described in usage of bimatoprost 0.03% and travoprost 0.004%. However this has not been reported in latanoprost instillation. Therefore, patients should be made aware of these potential side effects. 

---